GlassScriptPhysician profile
Peter J Luea
NPI 1780639880
$4,558.54
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $454 · 2021: $768 · 2022: $1,129 · 2023: $1,074 · 2024: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.38 | 2021-2024 | |
| Novo Nordisk INC | $525.13 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $459.81 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $380.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $367.30 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $206.73 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.28 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $169.41 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Teva Pharmaceuticals USA, INC. | $113.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $97.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.19 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $85.29 | 2021-2023 | Rexulti |
| Exact Sciences Corporation | $80.38 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $75.49 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Luea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.